Back to mobile site

Form SCHEDULE 13G/A Protalix BioTherapeutics Filed by: MAK Capital Fund LP

March 30, 2026 5:35 PM EDT





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
   Rule 13d-1(b)
   Rule 13d-1(c)
   Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person:  The calculation is based upon 3,616,289 shares of Common Stock beneficially owned as of 03/30/2026 and a total of 80,421,181 shares of Common Stock, $0.001 par value per share, outstanding as of November 1, 2025, as reported by the Issuer in its Form 10-Q filed November 13, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person:  The calculation is based upon 3,616,289 shares of Common Stock beneficially owned as of 03/30/2026 and a total of 80,421,181 shares of Common Stock, $0.001 par value per share, outstanding as of November 1, 2025, as reported by the Issuer in its Form 10-Q filed November 13, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person:  The calculation is based upon 3,616,289 shares of Common Stock beneficially owned as of 03/30/2026 and a total of 80,421,181 shares of Common Stock, $0.001 par value per share, outstanding as of November 1, 2025, as reported by the Issuer in its Form 10-Q filed November 13, 2025.


SCHEDULE 13G



 
MAK Capital Fund LP
 
Signature:/s/ Michael A. Kaufman
Name/Title:Managing Member
Date:03/30/2026
 
MAK CAPITAL ONE LLC
 
Signature:/s/ Michael A. Kaufman
Name/Title:Managing Member
Date:03/30/2026
 
Kaufman Michael A
 
Signature:/s/ Michael A. Kaufman
Name/Title:Michael A. Kaufman
Date:03/30/2026

ATTACHMENTS / EXHIBITS

EXHIBIT 99.1



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

SEC Filings

Related Entities

MAK Capital One, 13G